Would you use abiraterone or docetaxel in addition to ADT and radiotherapy for patients with very high risk, node-negative prostate cancer?

The most recent update from STAMPEDE's abiraterone arm in the M0 N0 very high risk setting was reported here: Attard et al., PMID 34953525 and strongly suggests that abi/ADT for 2 years plus radiation improves MFS and OS significantly and should be standard of care for men who are choosing RT in thi...

Results from the initial STAMPEDE study and the subsequent STAMPEDE arm G included a subset of patients who fit the definition of high-risk, node negative prostate cancer. In both studies, failure free survival was improved by the addition of docetaxel and abiraterone respectively, overall survival ...